Richard Aplenc
Professor of Pediatrics (Oncology) at the Children's Hospital of Philadelphia
Physican, The Children's Hospital of Philadelphia
Department: Pediatrics
Contact information
Colket Translational Research Building
Suite 4060
3501 Civic Center Blvd
Philadelphia, PA 19104
Suite 4060
3501 Civic Center Blvd
Philadelphia, PA 19104
Office: 267-426-7252
Email:
aplenc@email.chop.edu
aplenc@email.chop.edu
Education:
A.B. (Classics)
Princeton University, 1988.
University of Pennsylvania, Post-Baccalaureate Pre-Health Program, 1989.
MD
University of Virginia, 1994.
MSCE (Clinical Epidemiology and Biostatistics)
University of Pennsylvania, 2002.
PhD (Epidemiology)
University of Pennsylvania, 2011.
A.B. (Classics)
Princeton University, 1988.
University of Pennsylvania, Post-Baccalaureate Pre-Health Program, 1989.
MD
University of Virginia, 1994.
MSCE (Clinical Epidemiology and Biostatistics)
University of Pennsylvania, 2002.
PhD (Epidemiology)
University of Pennsylvania, 2011.
Post-Graduate Training
Internship and Residency in Pediatrics, University of California at San Diego, 1994-1997.
Fellowship in Pediatric Hematology/Oncology, The Children's Hospital of Philadelphia, 1997-2000.
Permanent linkInternship and Residency in Pediatrics, University of California at San Diego, 1994-1997.
Fellowship in Pediatric Hematology/Oncology, The Children's Hospital of Philadelphia, 1997-2000.
Description of Itmat Expertise
Dr. Aplenc's research involves molecular epidemiology, pediatric cancer Phase I clinical trials, treatment of pediatric AML, and the use of genetic polymorphism data to predict treatment response to therapeutic interventions, particularly in pediatric cancer therapy.Selected Publications
Ruiz J, Kelly RK, Aplenc R, Laetsch TW, Seif AE: Absolute Neutrophil Count Clinical Trial Eligibility Criteria for Pediatric Oncology Phase I and Phase I/II Trials by Sponsorship. Pediatr Blood Cancer 71(5), May 2024 Notes: doi: 10.1002/pbc.30925.Newman H, Li Y, Huang YV, Elgarten CW, Myers RM, Ruiz J, Zheng DJ, Barz Leahy A, Aftandilian C, Arnold SD, Bona K, Gramatges MM, Heneghan MB, Maloney KW, Modi AJ, Mody RJ, Morgan E, Rubnitz J, Winick N, Wilkes JJ, Seif AE, Fisher BT, Aplenc R, Getz KD: Household income and health-related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research. Cancer Med 13(7), Apr 2024 Notes: doi: 10.1002/cam4.6966.
Abla O, Ries RE, Triche Jr TJ, Gerbing RB, Hirsch B, Raimondi S, Cooper TM, Farrar JE, Buteyn N, Harmon LM, Wen H, Deshpande AJ, Kolb EA, Gamis AS, Aplenc R, Alonzo T, Meshinchi S: Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood Adv 8(8): 2005-2017, Apr 2024 Notes: doi: 10.1182/bloodadvances.2023010805.
Van Weelderen RE, Harrison CJ, Klein K, Jiang Y, Abrahamsson J, Alonzo T, Aplenc R, Arad-Cohen N, Bart-Delabesse E, Buldini B, De Moerloose B, Dworzak MN, Elitzur S, Fernandez Navarro JM, Gamis AS, Gerbing RB, Goemans BF, De Groot-Kruseman HA, Guest EM, Ha SY, Hasle H, Kelaidi C, Lapillone H, Leverger G, Locatelli F, Miyamura T, Noren-Nystrom U, Polychronopoulou S, Rasche M, Rubnitz JE, Stary J, Tierens A, Tomizawa D, Zwaan MC, Kaspers GJL: Optimized Cytogenetic Risk-Group Stratification of KMT2A-Rearranged Pediatric Acute Myeloid Leukemia. Blood Adv Apr 2024 Notes: doi: 10.1182/bloodadvances.2023011771.
Talleur AC, Fabrizio VA, Aplenc R, Grupp SA, Mackall C, Majzner R, Nguyen R, Rouce R, Moskop A, McNerney KO: INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults. Transplant Cell Ther Apr 2024 Notes: doi: 10.1016/j.jtct.2024.04.004.
Renaud J, Goemans BF, Locatelli F, Pigazzi M, Redmond S, Kuehni CE, Destaillats A, Alonzo TA, Gerbing RB, Gamis A, Aplenc R, Renella R, Cooper T, Ceppi F: Characteristics and treatment of acute myeloid neoplasms with cutaneous involvement in infants up to 6 months of age: A retrospective study. Pediatr Blood Cancer Apr 2024 Notes: doi: 10.1002/pbc.31006.
Cao L, Huang Y, Getz KD, Seif AE, Ruiz J, Miller TP, Fisher BT, Aplenc R, Li Y: Applying machine learning to identify pediatric patients with newly diagnosed acute lymphoblastic leukemia using administrative data. Pediatr Blood Cancer 71(3), Mar 2024 Notes: doi: 10.1002/pbc.30858.
Ruiz J, Li Y, Cao L, Huang YV, Tam V, Griffis HM, Winestone LE, Fisher BT, Alonzo TA, Wang YJ, Dang AT, Kolb EA, Glanz K, Getz KD, Aplenc R, Seif AE: Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia. Cancer 130(6): 962-972, Mar 2024 Notes: doi: 10.1002/cncr.35109.
Myers RM, Devine KJ, Li Y, Lawrence S, Barz Leahy A, Liu H, Vernau L, Callahan C, Baniewicz D, Kadauke S, McGuire R, Wertheim G, Kulikovskaya I, Gonzales V, Fraietta JA, DiNofia A, Hunger SP, Rheingold SR, Aplenc R, June CH, Grupp SA, Wray L, Maude SL: Reinfusion of CD19 CAR T Cells for Relapse Prevention and Treatment in Children with Acute Lymphoblastic Leukemia. Blood Adv Feb 2024 Notes: doi: 10.1182/bloodadvances.2024012885.
Menssen AJ, Hudson CA, Alonzo T, Gerbing R, Pardo L, Leonti A, Cook JA, Hsu F, Lott LL, Dai F, Fearing C, Ghirardelli K, Hylkema T, Tarlock K, Loeb KR, Kolb EA, Cooper T, Pollard J, Wells DA, Loken MR, Aplenc R, Meshinchi S, Eidenschink Brodersen L: CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group. Haematologica Feb 2024 Notes: doi: 10.3324/haematol.2023.283757.